CytomX raises $30m in Series B funding
CytomX Therapeutics, a San Francisco-based biotechnology company, has completed a $30 million Series B financing round, the company announced. The round was led by Third Rock Ventures with help from the Roche Venture Fund. CytomX, which develops antibodies, will be using the funds to fund further research and move the company to the Bay Area.
23 September 2010•3 mins read
